Nanobiotix SA (NBTX)

Voting Rights and Shares Capital of the Company

PARIS, June 05, 2026 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code:...

Nanobiotix Provides First Quarter 2026 Operational and Financial Update

Completed a follow-on offering in May 2026 for aggregate gross proceeds of approximately €86.1 million...

Nanobiotix Joins the Euronext Tech Leaders Index

PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the...

NANOBIOTIX Announces Closing of Global Offering

PARIS and CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX –...

NANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million

PARIS and CAMBRIDGE, Mass., May 22, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX –...

Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering

PARIS, France and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –...

Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris

PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX –...

Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris

PARIS and CAMBRIDGE, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX –...

Nanobiotix Announces Launch of Global Follow-On Offering

PARIS and CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX –...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer

PARIS and CAMBRIDGE, Mass., May 17, 2026 (GLOBE NEWSWIRE) --  NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the...

Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study

PARIS and CAMBRIDGE, Mass., May 04, 2026 (GLOBE NEWSWIRE) --  NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX –...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]